Evaluation of the use of Proluton-Depot (hydroxyprogesterone hexanoate) in early pregnancy

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 20(1), 13-17

DOI 10.1016/0020-7292(82)90039-x PMID 6126401 Source

Abstract

This study evaluates the effect of treatment with Proluton-Depot (hydroxyprogesterone hexanoate) in early pregnancy, and the final outcome of pregnancy and fetal status. One hundred and fifty patients received intramuscular injection of Proluton-Depot from 6 weeks to 8 weeks to 16 weeks to 18 weeks gestation. The outcome of this treated group was compared with a similar number of 150 patients with similar problems, but the second group received no hormonal treatment. There was no evidence to suggest that Proluton-Depot had any adverse effect on the infant or the final outcome of pregnancy.

Topics

hydroxyprogesterone hexanoate early pregnancy, proluton depot pregnancy support, progesterone supplementation early pregnancy, 17-ohp pregnancy outcomes, progesterone injections first trimester, luteal phase support pregnancy, hydroxyprogesterone caproate pregnancy, progesterone supplementation miscarriage prevention, intramuscular progesterone early pregnancy, progestogen support threatened abortion, progesterone pregnancy maintenance

Cite this article

Varma, T. R., & Morsman, J. (1982). Evaluation of the use of Proluton-Depot (hydroxyprogesterone hexanoate) in early pregnancy. *International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics*, *20*(1), 13-17. https://doi.org/10.1016/0020-7292(82)90039-x

Related articles